Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec, a Germany-based discoverer and developer of novel small molecule drugs, has signed an agreement to acquire all the shares of Munich-based Kinaxo Biotechnologies for EUR12m (consisting of EUR3m in cash and 2.6m in shares) in addition to earn-out payments of up to EUR4m depending on performance.
Subscribe to our email newsletter
Kinaxo’s acquisition establishes Evotec‘s as an integrated drug discovery and early development partner for pharma and biotechnology companies.
Kinaxo’s novel technologies are expected to help Evotec arrive at informed decisions on drug efficacy, safety and response in patients.
Evotec CEO Werner Lanthaler said the company gains access to a highly innovative technology base in drug discovery by acquiring Kinaxo.
Kinaxo CEO Andreas Jenne said their technology portfolio perfectly fitted into Evotec’s integrated service offering which will help them leverage their capabilities and grow business much faster.
Kinaxo co-founder and director of the Martinsried-based Max-Planck-Institute for Biochemistry Axel Ullrich said the integration of the leading drug discovery capability will implement Evotec as a driver towards personalised medicine in the future.